Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Numéro 4, Avril 2005
Page(s) 405 - 411
Section M/S revues
DOI https://doi.org/10.1051/medsci/2005214405
Publié en ligne 15 avril 2005
  1. Wollfe AP, Matzke MA. Epigenetics : regulation through repression. Science 1999; 286 : 481–6.
  2. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Genet 2002; 3 : 662–73.
  3. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429 : 457–63.
  4. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18 : 2315–35.
  5. Jones PA, Baylin SB. The fundamental roles of epigenetic events in cancer. Nat Rev Genet 2002; 3 : 415–28.
  6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349 : 2042–54.
  7. Hake SB, Xiao A, Allis CD. Linking the epigenetic language of covalent histone modifications to cancer. Br J Cancer 2004; 90 : 761–9.
  8. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4 : 143–53.
  9. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16 : 6–21.
  10. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9 : 2395–402.
  11. Fuks F. Les méthyltransférases de l’ADN : du remodelage de la chromatine au cancer. Med Sci (Paris) 2003; 19 : 477–80.
  12. Ting AH, Jair KW, Suzuki H, et al. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet 2004; 36 : 582–4.
  13. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416 : 552–6.
  14. Claus R, Lübbert M. Epigenetic target in hematopietic malignancies. Oncogene 2003; 22 : 6489–96.
  15. Filion G, Defossez PA. Les protéines se liant à l’ADN méthylé : interprètes du code épigénétique. Med Sci (Paris) 2004; 20 : 7–8.
  16. Xu GL, Bestor TH, Bourc’his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402 : 187–91.
  17. Kriaucionis S, Bird A. DNA methylation and Rett syndrome. Hum Mol Genet 2003; 12 : 221–7.
  18. Chen WY, Zeng X, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 2003; 33 : 197–202.
  19. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293 : 1074–80.
  20. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002; 12 : 198–209.
  21. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23 : 4225–31.
  22. Schneider R, Bannister A, Kouzarides T. Unsafe SETs : histone lysine methyltransferases and cancer. Trends Biochem Sci 2002; 27 : 396–402.
  23. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14 : 155–64.
  24. Roberts CWM, Orkin SH. The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 2004; 4 : 133–42.
  25. Fujita N, Jaye DL, Kajita M, et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003; 113 : 207–19.
  26. Fahrner JA, Baylin, SB. Heterochromatin : stable and unstable invasions at home and abroad. Genes Dev 2003; 17 : 1805–12.
  27. Villar-Garea A, Esteller M. DNA demethylating agents and chromatin-remodelling drugs : which, how and why. Curr Drug Metab 2003; 4 : 11–31.
  28. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3 : 89–95.
  29. Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004; 6 : 361–71.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.